1. Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection

   • Catia Marzolini
   • Sara Gibbons
   • Saye Khoo

   Commentary 14 December 2021 Pages: 339 - 346

2. Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat

   • David Czock
   • Frieder Keller

   Review Article Open access 14 December 2021 Pages: 347 - 362

   

3. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin

   • Kyle C. Molina
   • Matthew A. Miller
   • Tyree H. Kiser

   Review Article 21 December 2021 Pages: 363 - 374

   

4. Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling

   • Maiara Camotti Montanha
   • Francesc Fabrega
   • Marco Siccardi

   Original Research Article Open access 12 October 2021 Pages: 375 - 386

   

5. Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis

   • Li Yan
   • Holly Kimko
   • William A. Rees

   Original Research Article Open access 31 October 2021 Pages: 387 - 400

   

6. Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study

   • Yunjiao Wu
   • Swantje Völler
   • Catherijne A. J. Knibbe

   Original Research Article Open access 13 November 2021 Pages: 401 - 412

   

7. Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus

   • Marshall Grant
   • Tim Heise
   • Robert Baughman

   Original Research Article Open access 13 November 2021 Pages: 413 - 422

   

8. The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

   • Amina Bensalem
   • Guillaume Cartron
   • David Ternant

   Original Research Article 13 November 2021 Pages: 423 - 437

   

9. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis

   • Paul van den Berg
   • Martijn Ruppert
   • Thomas Eissing

   Original Research Article Open access 13 November 2021 Pages: 439 - 450

   

10. Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

    • Sebastiaan Camiel Goulooze
    • Nelleke Snelder
    • Thomas Eissing

    Original Research Article Open access 17 November 2021 Pages: 451 - 462

    

11. Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions

    • Marie-Emilie Willemin
    • Thomas K. Van Der Made
    • Jan Snoeys

    Correction 17 February 2022 Pages: 463 - 463